Objective-Nitric oxide (NO) is an important modulator of cardiovascular function. In this study, we examined whether cytosolic phospholipase A 2 ␣ (cPLA 2 ␣), an initial enzyme in the arachidonic acid pathway, is involved in blood pressure (BP) elevation in a murine model of chronic NO inhibition. Methods and Results-cPLA 2 ␣ gene-deficient mice (cPLA 2 ␣Ϫ/Ϫ) and wild-type mice (WT) were administered the NO synthesis inhibitor N -nitro-L-arginine methyl ester (L-NAME) for 4 weeks. Before treatment, BP was comparable in both groups; it increased significantly in the WT but not in the cPLA 2 ␣Ϫ/Ϫ after treatment. Bone marrow transplantation experiments showed that cPLA 2 ␣ in blood cells and plasma eicosanoid concentrations were not involved in BP elevation by L-NAME treatment. Activation of cPLA 2 ␣ and subsequent production of eicosanoids in the aortic endothelium but not in aortic smooth muscle cell, heart, or kidney was observed after L-NAME treatment. Aortic ring assays revealed that endothelial function was comparable in both groups of mice before treatment. L-NAME treatment disturbed endothelial function in WT but not in cPLA 2 ␣Ϫ/Ϫ. Conclusion-These results suggest that endothelial cPLA 2 ␣ may play a principal role in L-NAME-induced hypertension and may be a target molecule for maintaining endothelial function under NO inhibition. (Arterioscler Thromb Vasc Biol. 2011;31:1133-1138.)
E ndothelial nitric oxide (NO) is an important modulator in the maintenance of blood pressure (BP) and vascular function because of its action as a vascular smooth muscle relaxant and antiinflammatory factor in the cardiovascular system. Although several experimental investigations have suggested that a decrease in NO activity induces hypertension, 1-6 arteriosclerosis, 7, 8 and myocardial infarction, 9, 10 the detailed mechanisms of these phenomena in the cardiovascular system are not fully understood.
The arachidonic acid (AA) cascade participates in the pathogenesis of acute and chronic inflammatory diseases, such as rheumatoid arthritis, 11, 12 bronchial asthma, [13] [14] [15] and atherosclerotic diseases 16 -19 ; modulators of this cascade are commonly used in clinical practice. Inhibition of the downstream enzymes of AA cascade, including cyclooxygenase (COX) and lipoxygenase (LOX), is reported to modulate elevations in BP caused by chronic NO synthase (NOS) inhibition induced by treatment with N -nitro-L-arginine methyl ester (L-NAME). 20, 21 However, involvement of organ-specific or tissue-specific production of the AA itself and the downstream metabolites in BP elevation under NOS inhibition has not been studied. Eicosanoids are produced in several tissues, including white blood cells, platelets, vascular smooth muscle cells (SMCs), vascular endothelial cells (ECs), and the kidney. Atherogenesis and the incidence of cardiovascular diseases are variably affected, depending on the specific tissue and degree of activation of the AA cascade. Therefore, to prevent cardiovascular diseases, it is important to realize the tissue-specific roles of the AA cascade.
Cytosolic phospholipase A 2 ␣ (cPLA 2 ␣) is one of the initial enzyme in the AA cascade, and it selectively cleaves AA from membrane phospholipids. There are reports that cPLA 2 ␣ gene-deficient mice (cPLA 2 ␣Ϫ/Ϫ), despite having disturbances in delivery, 22, 23 have preserved normal physiological function, including BP and growth. 24, 25 Under several stimulations that lead to acute and chronic inflammation, deficiency of cPLA 2 ␣ protects against organ injury 11, 14, 15, 22, 23 by overall suppressing downstream production of eicosanoids.
In this study, we examined the roles of cPLA 2 ␣ on BP levels during chronic inhibition of NO in cPLA 2 ␣Ϫ/Ϫ.
Methods

L-NAME Administration and BP Measurement
L-NAME (100 mg/kg per day, Sigma-Aldrich, St Louis, MO) was administered to the wild-type mice (WT) and cPLA 2 ␣Ϫ/Ϫ in their drinking water for 2 or 4 weeks. Systolic BP (SBP) and diastolic BP (DBP) were determined 3 times in conscious and restrained mice using a noninvasive tail-cuff device (KN-214 II Softron, Tokyo, Japan) by a researcher who was blinded to the genotypes and treatment group of the animals. BP was expressed as the average of the measurements in each mouse.
Aorta-Ring Experiments
Animals and Tissue Preparation
Mice were anesthetized by intraperitoneal infusion of pentobarbital (50 mg/kg, Kyoritsu, Tokyo, Japan) followed by rapid and careful excision of the thoracic aortas, which were then placed in an ice-cold physiological salt solution (PSS) (123 mmol/L NaCl, 4.7 mmol/L KCl, 15.5 mmol/L NaHCO 3 , 1.2 mmol/L KH 2 PO 4 , 1.2 mmol/L MgCl 2 , 1.25 mmol/L CaCl 2 , and 11.5 mmol/L D-glucose). The fat and adventitia were dissected free under a binocular microscope, and the aortas were then cut transversely into 3-to 4-mm-long rings. In some experiments, the endothelium was removed by the same method for Western blotting.
Isometric Force Measurement
The vascular rings were mounted onto 2 tungsten wires in PSS maintained at 37.0Ϯ0.5°C and aerated with a gas mixture of 95% O 2 and 5% CO 2 to give a pH of 7.3 to 7.4. One wire was fixed, and the other wire was connected to a force transducer (type 45196A, San-ei Instruments, Tokyo, Japan). The resting tension was adjusted to 1.0g which was optimal for obtaining maximum contractile response to a 60 mmol/L KCl solution. Norepinephrine (NE) and acetylcholine (Ach) were obtained from Sigma-Aldrich.
Measurement of Eicosanoids
Blood samples were obtained by the puncture at right ventricle at the time of euthanization, indomethacin/EDTA treated plasma were separated and stored at -80°C until the eicosanoids were measured. Aortas were prepared using the same procedure as the aortic ring experiments and cultured in PSS at 37°C for 30 minutes. After incubation, PSS was collected and preserved at -80°C. The aortas were then dried, and their dry weights were measured. The concentrations of thromboxane B 2 (TXB 2 ), 6-keto-prostaglandin F 1 ␣ (PGF 1 ␣), leukotriene B 4 (LTB 4 ), and cysLTs in the PSS were quantified by commercially available enzyme-linked immunosorbent assays (Cayman Chemical Co) according to the manufacturer's instructions.
Statistical Analysis
The data were analyzed using StatView J-4.5 software (SAS Inc). Values are expressed as meanϮSD. Because all values were shown to have equal variance, comparisons between values of the groups were performed using the Student t test. Probability values Ͻ0.05 were considered to imply significant differences between the groups.
Results
BP
There was no significant difference in the volume of drinking water, body weight increase, or appearance between any of the treatment groups (unpublished data). Before L-NAME treatment, SBP and DBP in the WT and cPLA 2 ␣Ϫ/Ϫ were comparable (WT: 106.6Ϯ6.1 and 64.6Ϯ3.9 mm Hg; cPLA 2 ␣Ϫ/Ϫ: 103.9Ϯ6.1 and 64.4Ϯ4.0 mm Hg, respectively, nϭ11 each, Figure 1 ). BP in WT started to increase 2 weeks after L-NAME treatment, with significant differences being sustained until 4 weeks after treatment compared with pretreatment values. In contrast, SBP and DBP did not increase in cPLA 2 ␣Ϫ/Ϫ following L-NAME treatment (nϭ11, Figure 1 ).
Bone Marrow Transplantation Experiment
We next evaluated which tissue was involved in BP elevation associated with L-NAME treatment. To investigate whether cPLA 2 ␣ in blood cells participated in the BP increases caused by L-NAME treatment, we performed the bone marrow transplantation (BMT) experiments. We prepared 4 groups, WT bone marrow (BM) to WT (WT3WT), cPLA 2 ␣Ϫ/Ϫ BM to WT (cPLA 2 ␣Ϫ/Ϫ3 WT), WT BM to cPLA 2 ␣Ϫ/Ϫ (WT3 cPLA 2 ␣Ϫ/Ϫ), and cPLA 2 ␣Ϫ/Ϫ BM to cPLA 2 ␣Ϫ/Ϫ (cPLA 2 ␣Ϫ/Ϫ3cPLA 2 ␣Ϫ/Ϫ), and 4 weeks after transplantation the baseline BP levels in BMT mice were comparable to those in the non-BMT mice ( Figure 2 ). Confirmation of the completion of BMT 4 weeks after transplantation was per- Figure 1 . BP changes following L-NAME treatment in WT and cPLA 2 ␣Ϫ/Ϫ. Two weeks after L-NAME administration, a significant and sustained elevation of SBP and DBP was observed in WT, whereas there was no elevation in BP in the cPLA 2 ␣Ϫ/Ϫ. nϭ11 per group. *PϽ0.01 vs the respective baseline value.
Figure 2.
Effect of cPLA 2 ␣ gene deficiency in blood cells on BP following L-NAME treatment. L-NAME administration caused a significant elevation in SBP and DBP in WT3 WT and cPLA 2 ␣Ϫ/Ϫ3 WT but not in WT3cPLA 2 ␣Ϫ/Ϫ or cPLA 2 ␣Ϫ/Ϫ3cPLA 2 ␣Ϫ/Ϫ. nϭ6 per group. *PϽ0.01 vs the respective baseline value.
formed by polymerase chain reaction, and at least 90% of peripheral blood cells in the recipient were confirmed in the donor derived cells (unpublished data). The levels of SBP and DBP in WT3 WT and cPLA 2 ␣Ϫ/Ϫ3 WT were significantly higher at 2 and 4 weeks after L-NAME treatment compared with pretreatment levels (nϭ6). However, there were no significant changes in SBP and DBP in the WT3cPLA 2 ␣Ϫ/Ϫ and cPLA 2 ␣Ϫ/Ϫ3cPLA 2 ␣Ϫ/Ϫ (nϭ6, Figure 2 ). These results suggested that cPLA 2 ␣ in blood cells was not responsible for the increases in BP induced by L-NAME treatment.
Plasma Concentration of Eicosanoid Levels
Plasma concentrations of TXB 2 , 6-keto-PGF 1 ␣, LTB 4 , and cysLTs were significantly lower in cPLA 2 ␣Ϫ/Ϫ compared with WT before L-NAME treatment, and these concentrations were not increased by L-NAME treatment in either group (nϭ11, *PϽ0.05, Supplemental Figure I , available online at http://atvb.ahajournals.org). These results indicated that plasma concentration of these eicosanoids may not be crucial in the physiological BP and the BP elevation by L-NAME treatment.
BMT experimental results suggested that plasma concentrations of TXB 2 and LTB 4 were regulated mainly by BM cells, and plasma concentration of 6-keto-PGF 1 ␣ was regulated dominantly by non-BM cells (tissue) in BMT experiments (Supplemental Figure IIA to IIC). Plasma concentration of cysLTs was regulated both BM cells and non-BM cells (Supplemental Figure IID) . Thus, BP elevation by L-NAME treatment could not be explained plausibly by the changes in plasma eicosanoid concentrations.
Plasma Renin Activity
Plasma renin activity in WT and cPLA 2 ␣Ϫ/Ϫ before L-NAME treatment was comparable (WT: 1.01Ϯ0.01 g/mL per 30 minutes; cPLA 2 ␣Ϫ/Ϫ: 1.01Ϯ0.01 g/mL per 30 minutes; nϭ5 each). No significant increase was observed by L-NAME treatment in both groups (WTϩL-NAME: 1.02Ϯ 0.01 g/mL per 30 minutes; cPLA 2 ␣Ϫ/ϪϩL-NAME: 1.01Ϯ0.01 g/mL per 30 minutes; nϭ5 each). cPLA 2 ␣ and Phospho-cPLA 2 ␣ Protein Levels, and PLA 2 Activity
We evaluated the effects of L-NAME treatment on cPLA 2 ␣ and phopho-cPLA 2 ␣ levels in thoracic aorta, kidney, and heart of WT. All these organs expressed cPLA 2 ␣, and the expression was most abundant in peripheral blood mononuclear cells and thoracic aorta ( Figure 3A) . Treatment with L-NAME did not increase the expression of cPLA 2 ␣ in any organs, whereas increased phosphorylation of cPLA 2 ␣ (p-cPLA 2 ␣) was observed in thoracic aorta but not in other organs compared with pretreatment values (nϭ6, PϽ0.05, Figure 3B , Supplemental Figure III) . In thoracic artery specimens, increased p-cPLA 2 ␣ level by L-NAME treatment was significantly decreased by endothelial denudation to the level of the untreated WT ( Figure 3B ). Furthermore, L-NAME administration significantly increased PLA 2 activity in the aorta, and an increase in PLA 2 activity was not observed after endothelium denudation ( Figure 3E ).
Tissue Culture PSS Eicosanoid Levels
Thoracic aorta were excised before and after L-NAME treatment and incubated in PSS, and the production of eicosanoids was measured. In WT, the production of TXB 2 , LTB 4 , and cysLTs by thoracic aorta were stimulated by L-NAME treatment, whereas the level of 6-keto-PGF 1 ␣ was not increased compared with pretreatment values (Figure 4 ). In cPLA 2 ␣Ϫ/Ϫ, the levels of eicosanoids were not affected by L-NAME treatment (nϭ6, PϽ0.05, Figure 4 ). Following L-NAME treatment, endothelium-denudation in arteries of WT reversed eicosanoid production to baseline (nϭ6, Figure  5 ). These results suggest that arterial endothelium is the tissue responsible for increased production of TXB 2 , LTB 4 , and cysLTs induced by L-NAME treatment, and these eicosanoids may be responsible for BP elevation following this treatment. Figure 3 . Effect of L-NAME treatment on cPLA 2 ␣ phosphorylation and PLA 2 activity. A, cPLA 2 ␣ protein expression in blood (peripheral blood mononuclear cells), heart, kidney, and aorta analyzed by Western blotting. Aorta and blood showed the highest expression levels of cPLA 2 ␣. B to D, Effect of L-NAME treatment on cPLA 2 ␣ and p-cPLA 2 ␣ protein expression in thoracic aorta of WT. E, PLA 2 activity in thoracic aorta of WT with L-NAME treatment. nϭ6 per group. *PϽ0.05. n.s. indicates not significant; EC-, endothelium denudation.
Figure 4.
Effect of L-NAME treatment on eicosanoid production from aorta of WT and cPLA 2 ␣Ϫ/Ϫ. L-NAME treatment significantly stimulated the production of TXB 2 (A), LTB 4 (C), and cys-LTs (D) but not 6-keto-PGF 1 ␣ (B) in WT aorta compared with untreated WT. There was no significant change in production of all the eicosanoids in cPLA 2 ␣Ϫ/Ϫ aorta following L-NAME treatment. nϭ6 per group. *PϽ0.05. n.s. indicates not significant.
Ex Vivo Aortic Reactivity
Finally, to investigate endothelium-dependent vasorelaxation, we contracted arteries by stimulation with NE and then coincubated the specimen with Ach. The Ach-induced relaxant responses in the aorta of WT and cPLA 2 ␣Ϫ/Ϫ before L-NAME treatment were comparable ( Figure 6A ), with these responses being abolished by endothelial denudation in both groups (unpublished data).
To elucidate the mechanism of endothelial dysfunction, we observed Ach-induced endothelium-dependent contractile responses of aorta from the mice treated with L-NAME for 2 weeks. Aorta from WT without pretreatment with L-NAME did not show any contractile response, whereas aorta from mice pretreated with L-NAME showed significant contractile response. These responses were abolished by endothelial denudation (Figure 6B ). Aorta from cPLA 2 ␣Ϫ/Ϫ pretreated with L-NAME did not show any contractile response. To elucidate the effects of L-NAME treatment on SMCs, a major component of the arterial wall, we investigated the NE-induced contractile responses in endothelial denuded arteries. Aorta from WT and cPLA 2 ␣Ϫ/Ϫ before and after 2 weeks of L-NAME treatment showed equivalent contractile responses ( Figure 6C ), which suggested that SMCs were not affected by L-NAME treatment.
Discussion
The main finding in this investigation was that BP elevations in WT caused by long-term inhibition of NO with L-NAME treatment were completely abolished in cPLA 2 ␣Ϫ/Ϫ. Experiments incorporating BMT revealed that a deficiency of cPLA 2 ␣ in blood cells was not responsible for this BP elevation. Furthermore, plasma concentration of eicosanoids did not play a crucial role for the BP alteration. cPLA 2 ␣ in aortic ECs was phosphorylated by L-NAME treatment, with these cells stimulating the production of downstream pressor/ vasoconstrictive eicosanoids.
In our aortic ring assays, although the contractile response in SMC was comparable in both groups of mice, endothelial dysfunction caused by L-NAME treatment was observed only in WT, whereas endothelial function was preserved in cPLA 2 ␣Ϫ/Ϫ. In a rat model of chronic NO inhibition resulting from L-NAME treatment, it was reported that inflammatory cardiovascular changes such as cardiac fibrosis and arterial hypertrophy occurred concomitantly with BP elevation. 26 -28 However, we observed no apparent abnormal appearance or pathological changes in either group of L-NAME-treated mice (Supplemental Figure IV) . We therefore considered the major mechanism of BP elevation caused by L-NAME treatment was attributable to pressor factors rather than cardiovascular structural remodeling. cPLA 2 ␣ is the initial enzyme of the AA cascade, and most of the downstream products of COX and LOX pathways are known pressor and vasoconstrictive eicosanoids as mediator of vasocontractility. 29 -33 It has been reported in a rat model that pharmacological inhibition of COX and LOX activity prevented BP elevation resulting from L-NAME treatment by inhibiting downstream eicosanoids. 20, 21 There is also evidence that BP elevation is suppressed in thromboxane-prostanoid receptor gene-deficient mice. 34 Although incomplete inhibition of BP elevation was achieved and the exact mechanism of this response was not elucidated, these results suggested that the AA cascade contributed to the BP elevation associated with chronic NO inhibition. On the other hand, in our investigation, the elevation in BP was completely prevented in cPLA 2 ␣Ϫ/Ϫ (Figure 1) . We therefore consider that simultaneous suppression of both pathways may synergistically prevent BP elevation caused by L-NAME treatment. The balance between the plasma concentration of vasodilative PGI 2 and vasoconstrictive TXA 2 is considered one of the important factors on pathophysiological BP alteration; however, our results (Supplemental Figure II) could not be Figure 5 . Endothelium-dependent eicosanoids production in aorta after L-NAME treatment. There was no significant difference in the production of eicosanoids by the aortic specimens without endothelium irrespective of L-NAME treatment. nϭ6 per group.
Figure 6. Ex vivo aorta ring assay. A, The relaxation response to
Ach under contraction with NE was comparable in WT and cPLA 2 ␣Ϫ/Ϫ. nϭ4 per group. B, The contractile response to Ach after L-NAME incubation was stimulated in L-NAME-treated WT but not in L-NAME-treated cPLA 2 ␣Ϫ/Ϫ. This contraction in WT was abolished by endothelial denudation. nϭ4 to 6 per group. *PϽ0.01 vs untreated WT. EC-indicates endothelial denudation. C, The contractile response to NE was comparable in WT and cPLA 2 ␣Ϫ/Ϫ and was not affected by endothelial denudation. nϭ5 per group.
explained by this theory. Long-term suppression of the COX-2 inhibitor has been reported to increase the incidence of cardiovascular events and atherogenesis, with this unfavorable effect considered to be the consequence of suppressed endothelial PGI 2 production. 35, 36 Plasma or urinary prostanoid concentrations do not appear to directly reflect pro-and antiatherogenic properties in vivo, 16, 18, 19 and therefore it is necessary to investigate the relationship between organ-specific production of each AA metabolite and their physiological roles in the cardiovascular system. BMT is a well-established experimental method for investigating the role of the AA cascade in blood cells. 17, 19, 37 We used this method to identify the organ responsible for this pressor response, as blood cells including platelets and leukocytes are major production sites of pressor/vasoconstrictive eicosanoids, including TXA 2 , LTB 4 , and cysLTs. 21,29 -32 However, contrary to our speculations, cPLA 2 ␣Ϫ/Ϫ in BM cells did not influence the BP elevation caused by L-NAME treatment (Figure 2 ). Our results showed that the aorta expressed high levels of cPLA 2 ␣. In addition, L-NAME treatment enhanced phosphorylation of cPLA 2 ␣ and PLA 2 activity in aortic endothelium, indicating that chronic NO synthesis inhibition leads to cPLA 2 ␣ activation in ECs (Figure 3 ). In accordance with the above results, the production of pressor/vasoconstrictive eicosanoids was stimulated in L-NAME-treated aortic endothelium (Figure 4) . When assayed in plasma, contrary to our expectation, L-NAME treatment did not affect eicosanoid levels (Supplemental Figure I ). This may be attributed to the production of eicosanoid from blood cells, which may mask the eicosanoid produced from endothelium.
In previous reports using an ex vivo aorta ring assay, it was suggested that inhibition of the COX and LOX pathways suppressed the endothelial-dependent pressor response associated with L-NAME treatment. 21, 38 In our study, the endothelial dysfunctional response was observed only in WT but not in cPLA 2 ␣Ϫ/Ϫ, whereas SMC-dependent contraction was comparable in both groups after L-NAME treatment ( Figure 6B and 6C ). Furthermore, as endothelial denudation abolished the L-NAME-induced dysfunction in WT aorta, we considered that several metabolites downstream of cPLA 2 ␣, including TXA 2 , cysLTs, and LTB 4 , were produced in dysfunctional endothelium following L-NAME treatment, leading to contraction of neighboring SMC and elevation of BP. TXA 2 and cysLTs are immediately metabolized in the circulating blood, and their high levels are maintained only at the sites of their production. 39, 40 Therefore, we think that eicosanoids are unlikely to have endocrine effects. We were unable to identify which metabolite was the primary stimulant and whether the other pressor hormones were also involved in this response; however, several investigations have already illustrated the involvement of the above eicosanoids in vasoconstriction in several degrees in aortic ring assay. 21,29 -32 We showed that the vasorelaxant and antiatherogenic prostanoid PGI 2 was reduced in arteries in cPLA 2 ␣Ϫ/Ϫ compared with WT, which may cause atherogenesis in vivo. However, the other atherogenic eicosanoids were also reduced in cPLA 2 ␣Ϫ/Ϫ (Figure 4) ; therefore, the balance between pro-and antiatherogenic eicosanoids needs to be investigated separately.
Inducible PLA 2 has been reported to play an important role in endothelium-dependent vasoconstriction, and secretary PLA 2 has been reported to have a relationship with BP. 41, 42 Further study of the relationships between inducible PLA 2 , secretary PLA 2 , and cPLA 2 to elucidate in more detail the relationship with BP control is necessary. Also, AA cascade is reported to be concerned in renin-angiotensin system. 43, 44 However, our results suggested that the renin-angiotensin system may not be involved in L-NAME-induced BP elevation ( Supplemental Table) . Although further detailed experiments are necessary to determine the exact mechanism, we demonstrated that total inhibition of the AA pathway resulted in complete suppression of BP elevation and that cPLA 2 ␣Ϫ/Ϫ did not show any physiological abnormal findings. This raises the possibility that total inhibition of the AA pathway by suppression of endothelial cPLA 2 ␣ is a potential antihypertensive strategy for conditions associated with endothelial dysfunction caused by NO inhibition.
In conclusion, we suggest that cPLA 2 ␣ plays an important role in BP elevation resulting from NO inhibition. Endothelial dysfunction due to hyperlipidemia, aging, diabetes mellitus, or other atherogenic risk factors leads to a decrease in NO production that is thought to be a contributing factor in the etiology of essential hypertension. Our results suggest the possibility that inhibition of cPLA 2 ␣ may be a new strategy for suppressing endothelial dysfunction and hypertensive disease.
